Updates on autoinflammatory diseases
Published by Elsevier Ltd..
Autoinflammatory diseases are hyperinflammatory, immune dysregulatory diseases caused by innate immune cells dysregulation that present typically in the perinatal period with systemic and organ-targeted inflammation, but with improved genetic testing and the development of diagnostic criteria, milder and later-onset forms are being detected in adulthood. While the discovery of gain-of-function mutations in innate sensors linked to the production of proinflammatory cytokines provided the bases for anti-cytokine therapies that changed disease and patient outcomes, the field is expanding with the increasing discovery of disease-causing loss-of-function mutations in genes with cellular house-keeping functions that affect cell homeostasis and when dysregulated trigger innate inflammatory pathways. This review focuses on updates on molecular pathways and diseases that cause predominantly IL-1β and Type-I IFN-mediated autoinflammatory diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2018 |
---|---|
Erschienen: |
2018 |
Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
---|---|
Enthalten in: |
Current opinion in immunology - 55(2018) vom: 05. Dez., Seite 97-105 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Martinez-Quiles, Narcisa [VerfasserIn] |
---|
Links: |
---|
Themen: |
Interferon Type I |
---|
Anmerkungen: |
Date Completed 25.09.2019 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.coi.2018.09.014 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM29085248X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM29085248X | ||
003 | DE-627 | ||
005 | 20231225065619.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2018 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.coi.2018.09.014 |2 doi | |
028 | 5 | 2 | |a pubmed24n0969.xml |
035 | |a (DE-627)NLM29085248X | ||
035 | |a (NLM)30453204 | ||
035 | |a (PII)S0952-7915(18)30105-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Martinez-Quiles, Narcisa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Updates on autoinflammatory diseases |
264 | 1 | |c 2018 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 25.09.2019 | ||
500 | |a Date Revised 08.04.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Published by Elsevier Ltd. | ||
520 | |a Autoinflammatory diseases are hyperinflammatory, immune dysregulatory diseases caused by innate immune cells dysregulation that present typically in the perinatal period with systemic and organ-targeted inflammation, but with improved genetic testing and the development of diagnostic criteria, milder and later-onset forms are being detected in adulthood. While the discovery of gain-of-function mutations in innate sensors linked to the production of proinflammatory cytokines provided the bases for anti-cytokine therapies that changed disease and patient outcomes, the field is expanding with the increasing discovery of disease-causing loss-of-function mutations in genes with cellular house-keeping functions that affect cell homeostasis and when dysregulated trigger innate inflammatory pathways. This review focuses on updates on molecular pathways and diseases that cause predominantly IL-1β and Type-I IFN-mediated autoinflammatory diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Intramural | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Review | |
650 | 7 | |a Interferon Type I |2 NLM | |
700 | 1 | |a Goldbach-Mansky, Raphaela |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Current opinion in immunology |d 1989-1990 |g 55(2018) vom: 05. Dez., Seite 97-105 |w (DE-627)NLM01261923X |x 1879-0372 |7 nnns |
773 | 1 | 8 | |g volume:55 |g year:2018 |g day:05 |g month:12 |g pages:97-105 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.coi.2018.09.014 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 55 |j 2018 |b 05 |c 12 |h 97-105 |